5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.06▲ | 2.07▼ | 2.07▼ | 1.91▲ | 1.80▲ |
MA10 | 2.06▲ | 2.07▼ | 2.07▼ | 1.82▲ | 1.80▲ |
MA20 | 2.07▼ | 2.02▲ | 1.96▲ | 1.80▲ | 1.71▲ |
MA50 | 2.02▲ | 1.88▲ | 1.82▲ | 1.78▲ | N/A |
MA100 | 1.93▲ | 1.80▲ | 1.78▲ | 1.71▲ | N/A |
MA200 | 1.83▲ | 1.78▲ | 1.75▲ | 2.17▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.006▼ | -0.006▼ | 0.005▲ | 0.037▲ | 0.061▲ |
RSI | 54.093▲ | 63.889▲ | 67.783▲ | 64.399▲ | 51.830▲ |
STOCH | 20.833 | 33.243 | 65.786 | 61.242 | 48.622 |
WILL %R | -62.500 | -60.714 | -23.611▲ | -20.408▲ | -14.085▲ |
CCI | 12.121 | -5.496 | 46.017 | 233.075▲ | 156.867▲ |
▼ RSI | $OSTX RSI(14) Crossed Below 70 | Set Alert |
Thursday, August 14, 2025 03:04 PM
OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology ...
|
Thursday, August 14, 2025 03:04 PM
OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology ...
|
Monday, July 28, 2025 09:25 AM
(Reuters) -The S&P 500 and the Nasdaq trimmed their gains after briefly reaching record highs on Monday, as investors looked past the U.S.-EU trade pact and braced for a week filled with megacap ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 2.15 | 2.15 | 2.02 | 2.06 | 484,200 |
14/08/25 | 1.88 | 2.16 | 1.71 | 2.15 | 951,700 |
13/08/25 | 1.81 | 1.89 | 1.80 | 1.88 | 459,000 |
12/08/25 | 1.69 | 1.78 | 1.6706 | 1.78 | 308,922 |
11/08/25 | 1.74 | 1.78 | 1.67 | 1.67 | 200,100 |
08/08/25 | 1.75 | 1.785 | 1.68 | 1.73 | 400,841 |
07/08/25 | 1.85 | 1.85 | 1.695 | 1.75 | 2,888,300 |
06/08/25 | 1.71 | 1.75 | 1.67 | 1.75 | 157,082 |
05/08/25 | 1.71 | 1.72 | 1.67 | 1.72 | 191,800 |
04/08/25 | 1.75 | 1.77 | 1.67 | 1.73 | 230,600 |
|
|
||||
|
|
||||
|
|